I agree that this site is using cookies. You can find further informations here.
X
Montalban, X.
426  results:
Search for persons X
?
1

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analys..:

Hauser, Steve L ; Kappos, L ; Montalban, X...
Multiple Sclerosis and Related Disorders.  80 (2023)  - p. 105308 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Factors associated with treatment escalation among MS speci..:

Saposnik, G. ; Andhavarapu, S. ; Fernández, Ó....
Multiple Sclerosis and Related Disorders.  58 (2022)  - p. 103404 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Four-year safety and effectiveness data from patients with ..:

Meca-Lallana, J. E. ; Oreja-Guevara, C. ; Muñoz, D....
PLOS ONE.  16 (2021)  10 - p. e0258437 , 2021
Link: https://doi.org/10.1371/..
 
?
4

P.048 International MAGNIMS-CMSC-NAIMS consensus recommenda..:

Traboulsee, A ; Wattjes, M ; Ciccarelli, O...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  48 (2021)  s3 - p. S32-S33 , 2021
Link: https://doi.org/10.1017/..
 
?
5

Optical coherence tomography measures correlate with brain ..:

Vidal‐Jordana, A. ; Pareto, D. ; Cabello, S....
European Journal of Neurology.  27 (2020)  11 - p. 2225-2232 , 2020
Link: https://doi.org/10.1111/..
 
?
6

The ACROSS study: Long-term efficacy of fingolimod in patie..:

Derfuss, T ; Sastre-Garriga, J ; Montalban, X...
Multiple Sclerosis Journal - Experimental, Translational and Clinical.  6 (2020)  1 - p. 205521732090795 , 2020
Link: https://doi.org/10.1177/..
 
?
7

Long-term safety data from the cladribine tablets clinical ..:

Leist, T. ; Cook, S. ; Comi, G....
Multiple Sclerosis and Related Disorders.  46 (2020)  - p. 102572 , 2020
Link: https://doi.org/10.1016/..
 
?
8

Hemophagocytic syndrome following alemtuzumab treatment for..:

Romero, A. ; Midaglia, L. ; Salcedo, M.T....
Multiple Sclerosis and Related Disorders.  40 (2020)  - p. 101973 , 2020
Link: https://doi.org/10.1016/..
 
?
9

P60 Long-term reduction of relapse rate and confirmed disab..:

Hauser, S.L. ; Hartung, H.P. ; Brochet, B....
Clinical Neurophysiology.  130 (2019)  8 - p. e170 , 2019
Link: https://doi.org/10.1016/..
 
?
10

Safety of ocrelizumab in multiple sclerosis: Updated analys..:

Hauser, S. ; Kappos, L. ; Montalban, X....
Journal of the Neurological Sciences.  405 (2019)  - p. 52 , 2019
Link: https://doi.org/10.1016/..
 
?
11

Long-term reduction of relapse rate and confirmed disabilit..:

Giovannoni, G. ; Kappos, L. ; Hauser, S.L....
Journal of the Neurological Sciences.  405 (2019)  - p. 308-309 , 2019
Link: https://doi.org/10.1016/..
 
?
12

FV 47 Safety of ocrelizumab in multiple sclerosis: updated ..:

Hauser, S. ; Hartung, H.P. ; Kappos, L....
Clinical Neurophysiology.  130 (2019)  8 - p. e142 , 2019
Link: https://doi.org/10.1016/..
 
?
13

Effectiveness of delayed-release dimethyl fumarate on patie..:

Berger, T ; Brochet, B ; Brambilla, L...
Multiple Sclerosis Journal - Experimental, Translational and Clinical.  5 (2019)  4 - p. 205521731988719 , 2019
Link: https://doi.org/10.1177/..
 
?
14

Kappa free light chains is a valid tool in the diagnostics ..:

Leurs, CE ; Twaalfhoven, HAM ; Lissenberg-Witte, BI...
Multiple Sclerosis Journal.  26 (2019)  8 - p. 912-923 , 2019
Link: https://doi.org/10.1177/..
 
?
15

P61 Sustained reduction in confirmed disability progression..:

Wolinsky, J.S. ; Hartung, H.P. ; Brochet, B....
Clinical Neurophysiology.  130 (2019)  8 - p. e170-e171 , 2019
Link: https://doi.org/10.1016/..
 
1-15